RXRX
NASDAQ · Biotechnology
Recursion Pharmaceuticals-A
$3.52
+0.02 (+0.57%)
Financial Highlights (FY 2026)
Revenue
102.87M
Net Income
-888,180,183
Gross Margin
5.0%
Profit Margin
-863.4%
Rev Growth
+23.3%
D/E Ratio
0.02
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 5.0% | 5.0% | 57.4% | 57.4% |
| Operating Margin | -880.9% | -792.8% | -4.6% | -4.6% |
| Profit Margin | -863.4% | -820.2% | -6.0% | -6.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 102.87M | 83.43M | 309.68M | 294.04M |
| Gross Profit | 5.13M | 4.16M | 177.76M | 168.78M |
| Operating Income | -906,150,477 | -661,423,705 | -14,369,694 | -13,411,310 |
| Net Income | -888,180,183 | -648,306,702 | -18,426,824 | -18,068,813 |
| Gross Margin | 5.0% | 5.0% | 57.4% | 57.4% |
| Operating Margin | -880.9% | -792.8% | -4.6% | -4.6% |
| Profit Margin | -863.4% | -820.2% | -6.0% | -6.2% |
| Rev Growth | +23.3% | +23.3% | +0.8% | +16.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 17.81M | 17.81M | 749.18M | 743.53M |
| Total Equity | 1.08B | 1.08B | 1.60B | 1.68B |
| D/E Ratio | 0.02 | 0.02 | 0.47 | 0.44 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -836,898,718 | -644,812,475 | -21,116,374 | -17,901,910 |
| Free Cash Flow | — | — | -13,211,156 | -10,972,266 |